In the changed post COVID-19 business landscape, the global market for Genitourinary Drugs estimated at US$27. 9 Billion in the year 2020, is projected to reach a revised size of US$28. 9 Billion by 2027, growing at a CAGR of 0.

New York, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Genitourinary Drugs Industry" - https://www.reportlinker.com/p06044618/?utm_source=GNW
5% over the analysis period 2020-2027. Urologicals, one of the segments analyzed in the report, is projected to record a 0.9% CAGR and reach US$5.9 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Hormonal Therapy Drugs segment is readjusted to a revised 0.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $8.1 Billion, While China is Forecast to Grow at 0.2% CAGR

The Genitourinary Drugs market in the U.S. is estimated at US$8.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$5.1 Billion by the year 2027 trailing a CAGR of 0.2% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 0.8% and 0.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 0.4% CAGR.

Gynecological products Segment to Record 0.7% CAGR

In the global Gynecological products segment, USA, Canada, Japan, China and Europe will drive the 0.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$851.6 Million in the year 2020 will reach a projected size of US$898.7 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 42 Featured) -
Astellas Pharma, Inc.
Bayer AG
Daiichi Sankyo Co., Ltd.
GlaxoSmithKline PLC
Otsuka Pharmaceutical Co., Ltd.
Pfizer, Inc.
Sanofi SA
Shandong Luoxin Pharmaceutical Group Stock co., ltd.
Yichang HEC Changjiang Pharmaceutical Company Limited


Read the full report: https://www.reportlinker.com/p06044618/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Genitourinary Drugs - Global Key Competitors Percentage Market
Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for
Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Recent Past, Current & Future Analysis for
Genitourinary Drugs by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Genitourinary Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Genitourinary Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets for Years 2012, 2021 & 2027

Table 4: World Recent Past, Current & Future Analysis for
Urologicals by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 5: World Historic Review for Urologicals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Urologicals by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 7: World Recent Past, Current & Future Analysis for
Hormonal Therapy Drugs by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for Hormonal Therapy Drugs by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for Hormonal Therapy Drugs
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 10: World Recent Past, Current & Future Analysis for
Gynecological products by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Gynecological products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Gynecological products
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 13: World Recent Past, Current & Future Analysis for
Anti-infectives by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 14: World Historic Review for Anti-infectives by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Anti-infectives by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 16: World Recent Past, Current & Future Analysis for
Other Products by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Other Products by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 18: World 15-Year Perspective for Other Products by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 19: World Recent Past, Current & Future Analysis for
Prostate Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Prostate Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Prostate Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 22: World Recent Past, Current & Future Analysis for
Ovarian Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Ovarian Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Ovarian Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 25: World Recent Past, Current & Future Analysis for
Bladder Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Bladder Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Bladder Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 28: World Recent Past, Current & Future Analysis for
Cervical Cancer by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Cervical Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Cervical Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 31: World Recent Past, Current & Future Analysis for
Renal Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 32: World Historic Review for Renal Cancer by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Renal Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 34: World Recent Past, Current & Future Analysis for
Erectile Dysfunction by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 35: World Historic Review for Erectile Dysfunction by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 36: World 15-Year Perspective for Erectile Dysfunction by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 37: World Recent Past, Current & Future Analysis for
Urinary Tract Infections by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 38: World Historic Review for Urinary Tract Infections by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 39: World 15-Year Perspective for Urinary Tract
Infections by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2021 & 2027

Table 40: World Recent Past, Current & Future Analysis for
Urinary Incontinence & Overactive Bladder by Geographic Region -
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World Markets - Independent Analysis of Annual Sales in US$
Million for Years 2020 through 2027 and % CAGR

Table 41: World Historic Review for Urinary Incontinence &
Overactive Bladder by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: World 15-Year Perspective for Urinary Incontinence &
Overactive Bladder by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2021 & 2027

Table 43: World Recent Past, Current & Future Analysis for
Sexually Transmitted Diseases by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 44: World Historic Review for Sexually Transmitted
Diseases by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 45: World 15-Year Perspective for Sexually Transmitted
Diseases by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2012, 2021 & 2027

Table 46: World Recent Past, Current & Future Analysis for
Benign Prostatic Hyperplasia by Geographic Region - USA,
Canada, Japan, China, Europe, Asia-Pacific and Rest of World
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 47: World Historic Review for Benign Prostatic
Hyperplasia by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 48: World 15-Year Perspective for Benign Prostatic
Hyperplasia by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2021 & 2027

Table 49: World Recent Past, Current & Future Analysis for
Other Indications by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 50: World Historic Review for Other Indications by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 51: World 15-Year Perspective for Other Indications by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2021 & 2027

Table 52: World Genitourinary Drugs Market Analysis of Annual
Sales in US$ Million for Years 2012 through 2027

III. MARKET ANALYSIS

UNITED STATES
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United States for 2022 (E)
Table 53: USA Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 54: USA Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological
products, Anti-infectives and Other Products Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 55: USA 15-Year Perspective for Genitourinary Drugs by
Product - Percentage Breakdown of Value Sales for Urologicals,
Hormonal Therapy Drugs, Gynecological products, Anti-infectives
and Other Products for the Years 2012, 2021 & 2027

Table 56: USA Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Ovarian
Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile
Dysfunction, Urinary Tract Infections, Urinary Incontinence &
Overactive Bladder, Sexually Transmitted Diseases, Benign
Prostatic Hyperplasia and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 57: USA Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer,
Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary
Tract Infections, Urinary Incontinence & Overactive Bladder,
Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 58: USA 15-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal
Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary
Incontinence & Overactive Bladder, Sexually Transmitted
Diseases, Benign Prostatic Hyperplasia and Other Indications
for the Years 2012, 2021 & 2027

CANADA
Table 59: Canada Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 60: Canada Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological
products, Anti-infectives and Other Products Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 61: Canada 15-Year Perspective for Genitourinary Drugs by
Product - Percentage Breakdown of Value Sales for Urologicals,
Hormonal Therapy Drugs, Gynecological products, Anti-infectives
and Other Products for the Years 2012, 2021 & 2027

Table 62: Canada Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Ovarian
Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile
Dysfunction, Urinary Tract Infections, Urinary Incontinence &
Overactive Bladder, Sexually Transmitted Diseases, Benign
Prostatic Hyperplasia and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 63: Canada Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer,
Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary
Tract Infections, Urinary Incontinence & Overactive Bladder,
Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 64: Canada 15-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal
Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary
Incontinence & Overactive Bladder, Sexually Transmitted
Diseases, Benign Prostatic Hyperplasia and Other Indications
for the Years 2012, 2021 & 2027

JAPAN
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Japan for 2022 (E)
Table 65: Japan Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 66: Japan Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological
products, Anti-infectives and Other Products Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 67: Japan 15-Year Perspective for Genitourinary Drugs by
Product - Percentage Breakdown of Value Sales for Urologicals,
Hormonal Therapy Drugs, Gynecological products, Anti-infectives
and Other Products for the Years 2012, 2021 & 2027

Table 68: Japan Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Ovarian
Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile
Dysfunction, Urinary Tract Infections, Urinary Incontinence &
Overactive Bladder, Sexually Transmitted Diseases, Benign
Prostatic Hyperplasia and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 69: Japan Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer,
Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary
Tract Infections, Urinary Incontinence & Overactive Bladder,
Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 70: Japan 15-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal
Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary
Incontinence & Overactive Bladder, Sexually Transmitted
Diseases, Benign Prostatic Hyperplasia and Other Indications
for the Years 2012, 2021 & 2027

CHINA
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in China for 2022 (E)
Table 71: China Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 72: China Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological
products, Anti-infectives and Other Products Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 73: China 15-Year Perspective for Genitourinary Drugs by
Product - Percentage Breakdown of Value Sales for Urologicals,
Hormonal Therapy Drugs, Gynecological products, Anti-infectives
and Other Products for the Years 2012, 2021 & 2027

Table 74: China Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Ovarian
Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile
Dysfunction, Urinary Tract Infections, Urinary Incontinence &
Overactive Bladder, Sexually Transmitted Diseases, Benign
Prostatic Hyperplasia and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 75: China Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer,
Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary
Tract Infections, Urinary Incontinence & Overactive Bladder,
Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 76: China 15-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal
Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary
Incontinence & Overactive Bladder, Sexually Transmitted
Diseases, Benign Prostatic Hyperplasia and Other Indications
for the Years 2012, 2021 & 2027

EUROPE
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Europe for 2022 (E)
Table 77: Europe Recent Past, Current & Future Analysis for
Genitourinary Drugs by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets - Independent Analysis of
Annual Sales in US$ Million for Years 2020 through 2027 and %
CAGR

Table 78: Europe Historic Review for Genitourinary Drugs by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets - Independent Analysis of Annual Sales in US$
Million for Years 2012 through 2019 and % CAGR

Table 79: Europe 15-Year Perspective for Genitourinary Drugs by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK and Rest of Europe Markets for Years
2012, 2021 & 2027

Table 80: Europe Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 81: Europe Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological
products, Anti-infectives and Other Products Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 82: Europe 15-Year Perspective for Genitourinary Drugs by
Product - Percentage Breakdown of Value Sales for Urologicals,
Hormonal Therapy Drugs, Gynecological products, Anti-infectives
and Other Products for the Years 2012, 2021 & 2027

Table 83: Europe Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Ovarian
Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile
Dysfunction, Urinary Tract Infections, Urinary Incontinence &
Overactive Bladder, Sexually Transmitted Diseases, Benign
Prostatic Hyperplasia and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 84: Europe Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer,
Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary
Tract Infections, Urinary Incontinence & Overactive Bladder,
Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 85: Europe 15-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal
Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary
Incontinence & Overactive Bladder, Sexually Transmitted
Diseases, Benign Prostatic Hyperplasia and Other Indications
for the Years 2012, 2021 & 2027

FRANCE
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in France for 2022 (E)
Table 86: France Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 87: France Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological
products, Anti-infectives and Other Products Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 88: France 15-Year Perspective for Genitourinary Drugs by
Product - Percentage Breakdown of Value Sales for Urologicals,
Hormonal Therapy Drugs, Gynecological products, Anti-infectives
and Other Products for the Years 2012, 2021 & 2027

Table 89: France Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Ovarian
Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile
Dysfunction, Urinary Tract Infections, Urinary Incontinence &
Overactive Bladder, Sexually Transmitted Diseases, Benign
Prostatic Hyperplasia and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 90: France Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer,
Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary
Tract Infections, Urinary Incontinence & Overactive Bladder,
Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 91: France 15-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal
Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary
Incontinence & Overactive Bladder, Sexually Transmitted
Diseases, Benign Prostatic Hyperplasia and Other Indications
for the Years 2012, 2021 & 2027

GERMANY
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in Germany for 2022 (E)
Table 92: Germany Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 93: Germany Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological
products, Anti-infectives and Other Products Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 94: Germany 15-Year Perspective for Genitourinary Drugs
by Product - Percentage Breakdown of Value Sales for
Urologicals, Hormonal Therapy Drugs, Gynecological products,
Anti-infectives and Other Products for the Years 2012, 2021 &
2027

Table 95: Germany Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Ovarian
Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile
Dysfunction, Urinary Tract Infections, Urinary Incontinence &
Overactive Bladder, Sexually Transmitted Diseases, Benign
Prostatic Hyperplasia and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 96: Germany Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer,
Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary
Tract Infections, Urinary Incontinence & Overactive Bladder,
Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 97: Germany 15-Year Perspective for Genitourinary Drugs
by Indication - Percentage Breakdown of Value Sales for
Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical
Cancer, Renal Cancer, Erectile Dysfunction, Urinary Tract
Infections, Urinary Incontinence & Overactive Bladder, Sexually
Transmitted Diseases, Benign Prostatic Hyperplasia and Other
Indications for the Years 2012, 2021 & 2027

ITALY
Table 98: Italy Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 99: Italy Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological
products, Anti-infectives and Other Products Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 100: Italy 15-Year Perspective for Genitourinary Drugs by
Product - Percentage Breakdown of Value Sales for Urologicals,
Hormonal Therapy Drugs, Gynecological products, Anti-infectives
and Other Products for the Years 2012, 2021 & 2027

Table 101: Italy Recent Past, Current & Future Analysis for
Genitourinary Drugs by Indication - Prostate Cancer, Ovarian
Cancer, Bladder Cancer, Cervical Cancer, Renal Cancer, Erectile
Dysfunction, Urinary Tract Infections, Urinary Incontinence &
Overactive Bladder, Sexually Transmitted Diseases, Benign
Prostatic Hyperplasia and Other Indications - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 102: Italy Historic Review for Genitourinary Drugs by
Indication - Prostate Cancer, Ovarian Cancer, Bladder Cancer,
Cervical Cancer, Renal Cancer, Erectile Dysfunction, Urinary
Tract Infections, Urinary Incontinence & Overactive Bladder,
Sexually Transmitted Diseases, Benign Prostatic Hyperplasia and
Other Indications Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 103: Italy 15-Year Perspective for Genitourinary Drugs by
Indication - Percentage Breakdown of Value Sales for Prostate
Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal
Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary
Incontinence & Overactive Bladder, Sexually Transmitted
Diseases, Benign Prostatic Hyperplasia and Other Indications
for the Years 2012, 2021 & 2027

UNITED KINGDOM
Genitourinary Drugs Market Presence - Strong/Active/Niche/
Trivial - Key Competitors in the United Kingdom for 2022 (E)
Table 104: UK Recent Past, Current & Future Analysis for
Genitourinary Drugs by Product - Urologicals, Hormonal Therapy
Drugs, Gynecological products, Anti-infectives and Other
Products - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 105: UK Historic Review for Genitourinary Drugs by
Product - Urologicals, Hormonal Therapy Drugs, Gynecological

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06044618/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001